326 related articles for article (PubMed ID: 34368630)
1. Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease.
Fowler C; Rainey-Smith SR; Bird S; Bomke J; Bourgeat P; Brown BM; Burnham SC; Bush AI; Chadunow C; Collins S; Doecke J; Doré V; Ellis KA; Evered L; Fazlollahi A; Fripp J; Gardener SL; Gibson S; Grenfell R; Harrison E; Head R; Jin L; Kamer A; Lamb F; Lautenschlager NT; Laws SM; Li QX; Lim L; Lim YY; Louey A; Macaulay SL; Mackintosh L; Martins RN; Maruff P; Masters CL; McBride S; Milicic L; Peretti M; Pertile K; Porter T; Radler M; Rembach A; Robertson J; Rodrigues M; Rowe CC; Rumble R; Salvado O; Savage G; Silbert B; Soh M; Sohrabi HR; Taddei K; Taddei T; Thai C; Trounson B; Tyrrell R; Vacher M; Varghese S; Villemagne VL; Weinborn M; Woodward M; Xia Y; Ames D;
J Alzheimers Dis Rep; 2021; 5(1):443-468. PubMed ID: 34368630
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
[No Abstract] [Full Text] [Related]
4. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
5. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
6. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
[TBL] [Abstract][Full Text] [Related]
7. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults.
Dang C; Harrington KD; Lim YY; Ames D; Hassenstab J; Laws SM; Yassi N; Hickey M; Rainey-Smith S; Robertson J; Sohrabi HR; Salvado O; Weinborn M; Villemagne VL; Rowe CC; Masters CL; Maruff P;
J Alzheimers Dis; 2018; 65(4):1313-1325. PubMed ID: 30149452
[TBL] [Abstract][Full Text] [Related]
9. Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative.
Ellis KA; Rowe CC; Villemagne VL; Martins RN; Masters CL; Salvado O; Szoeke C; Ames D;
Alzheimers Dement; 2010 May; 6(3):291-6. PubMed ID: 20451879
[TBL] [Abstract][Full Text] [Related]
10. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.
Ellis KA; Bush AI; Darby D; De Fazio D; Foster J; Hudson P; Lautenschlager NT; Lenzo N; Martins RN; Maruff P; Masters C; Milner A; Pike K; Rowe C; Savage G; Szoeke C; Taddei K; Villemagne V; Woodward M; Ames D;
Int Psychogeriatr; 2009 Aug; 21(4):672-87. PubMed ID: 19470201
[TBL] [Abstract][Full Text] [Related]
11. Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral Aβ-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study.
Gardener SL; Rainey-Smith SR; Villemagne VL; Fripp J; Doré V; Bourgeat P; Taddei K; Fowler C; Masters CL; Maruff P; Rowe CC; Ames D; Martins RN;
Front Aging Neurosci; 2021; 13():744872. PubMed ID: 34867277
[No Abstract] [Full Text] [Related]
12. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
13. Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study.
Ellis KA; Rainey-Smith SR; Rembach A; Macaulay SL; Villemagne VL;
Int Rev Psychiatry; 2013 Dec; 25(6):699-710. PubMed ID: 24423223
[TBL] [Abstract][Full Text] [Related]
14. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
15. A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.
Villemagne VL; Rowe CC; Barnham KJ; Cherny R; Woodward M; Bozinosvski S; Salvado O; Bourgeat P; Perez K; Fowler C; Rembach A; Maruff P; Ritchie C; Tanzi R; Masters CL
Alzheimers Dement (N Y); 2017 Nov; 3(4):622-635. PubMed ID: 29201996
[TBL] [Abstract][Full Text] [Related]
16. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
17. BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease.
Lim YY; Laws SM; Perin S; Pietrzak RH; Fowler C; Masters CL; Maruff P;
Genes Brain Behav; 2021 Jun; 20(5):e12724. PubMed ID: 33369083
[TBL] [Abstract][Full Text] [Related]
18. The ROSAS Cohort: A Prospective, Longitudinal Study of Biomarkers for Alzheimer's Disease. Strategy, Methods and Initial Results.
de Mauléon A; Soto M; Kiyasova V; Delrieu J; Guignot I; Galtier S; Lilamand M; Cantet C; Lala F; Sastre N; Andrieu S; Pueyo M; Ousset PJ; Vellas B
J Prev Alzheimers Dis; 2017; 4(3):183-193. PubMed ID: 29182709
[TBL] [Abstract][Full Text] [Related]
19. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
20. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
